Provided by Tiger Trade Technology Pte. Ltd.

Vaxart, Inc.

0.3700
+0.00661.82%
Volume:277.54K
Turnover:100.40K
Market Cap:88.64M
PE:-1.38
High:0.3700
Open:0.3634
Low:0.3550
Close:0.3634
52wk High:0.9800
52wk Low:0.2850
Shares:239.56M
Float Shares:226.93M
Volume Ratio:0.52
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2679
EPS(LYR):-0.3312
ROE:-106.52%
ROA:-16.25%
PB:3.31
PE(LYR):-1.12

Loading ...

Vaxart Inc. Director W. Mark Watson Acquires Common Shares

Reuters
·
Dec 06

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dow Jones
·
Dec 02

Vaxart Director Elaine J. Heron Reports Acquisition of Common Shares

Reuters
·
Nov 22

Vaxart (OTC: VXRT) Q3 EPS $(0.04) Up From $(0.06) YoY, Sales $72.41M Up From $4.93M YoY

Benzinga
·
Nov 14

Vaxart to Host Upcoming Conference Calls

GlobeNewswire
·
Nov 07

Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program

Reuters
·
Nov 06

Vaxart Secures $30 Million From Dynavax for Oral COVID-19 Vaccine License

Reuters
·
Nov 06

Vaxart Inc - to Receive $25 Mln Upfront and $5 Mln Equity Investment

THOMSON REUTERS
·
Nov 06

Vaxart Inc - May Receive up to $195 Mln in Regulatory Milestones

THOMSON REUTERS
·
Nov 06

Vaxart Inc - Dynavax to Pay Additional $50 Mln Fee to Vaxart

THOMSON REUTERS
·
Nov 06

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral Covid-19 Vaccine Program

THOMSON REUTERS
·
Nov 06

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

GlobeNewswire
·
Oct 20

Vaxart Inc - Barda Intends to Conclusively Delimit Project Agreement to Exclude Paused Work - SEC Filing

THOMSON REUTERS
·
Oct 11

Vaxart Inc - 5,000 Participants in Trial to Continue Follow-up - SEC Filing

THOMSON REUTERS
·
Oct 11

Vaxart Inc - to Continue Receiving Funding for Participant Evaluation - SEC Filing

THOMSON REUTERS
·
Oct 11

Trump Excludes Generics From Big Pharma Tariff Plan

Dow Jones
·
Oct 09

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

GlobeNewswire
·
Oct 08

Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements

Reuters
·
Sep 23

Vaxart wthdraws reverse stock split proposal

TIPRANKS
·
Sep 19

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

GlobeNewswire
·
Sep 19